Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| Ad5 | Adenovirus serotype 5 |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| ASP | Average sales price |
| BC | Bladder cancer |
| BCG | Bacillus Calmette-Guérin |
| BCG-UR | BCG-unresponsive |
| BIA | Budget impact analysis |
| BLA | Biologics license application |
| BSL-2 | Biosafety level 2 |
| BST | Bladder-sparing therapy |
| CFS | Cystectomy-free survival |
| CI | Confidence interval |
| CIS | Carcinoma in situ |
| CMS | Centers for Medicare and Medicaid Services |
| COST | Comprehensive Score for Financial Toxicity |
| CPT | Current Procedural Terminology |
| CR | Complete response |
| CRR | Complete response rate |
| CSS | Cancer-specific survival |
| CT | Computed tomography |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CTU | Computed tomography urography |
| DDM | n-dodecyl-β-D-maltoside |
| DFS | Disease-free survival |
| DOR | Duration of response |
| EAU | European Association of Urology |
| ECOG | Eastern Cooperative Oncology Group |
| EFS | Event-free survival |
| EORTC | European Organisation for Research and Treatment of Cancer |
| FDA | U.S. Food and Drug Administration |
| FT | Financial toxicity |
| GAG | Glycosaminoglycan |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| HCPCS | Healthcare Common Procedure Coding System |
| HG | High grade |
| HG-EFS | High-grade event-free survival |
| HG-RFS | High-grade recurrence-free survival |
| HGUC | High-grade urothelial carcinoma |
| HR | Hazard ratio |
| ICER | Institute for Clinical and Economic Review |
| IL-15 | Interleukin-15 |
| INN | International nonproprietary name |
| IQR | Interquartile range |
| ITT | Intention to treat |
| IVE | Intravesical |
| MedDRA | Medical Dictionary for Regulatory Activities |
| MFS | Metastasis-free survival |
| MIBC | Muscle-invasive bladder cancer |
| MMC | Mitomycin C |
| MRD | Minimal residual disease |
| MRI | Magnetic resonance imaging |
| MRU | Magnetic resonance urography |
| NAI | Nogapendekin alfa inbakicept |
| NMIBC | Non-muscle-invasive bladder cancer |
| OS | Overall survival |
| PD-L1 | Programmed death-ligand 1 |
| PDQ | Physician Data Query |
| PFS | Progression-free survival |
| PMPM | Per member per month |
| QALY | Quality-adjusted life year |
| QoL | Quality of life |
| RC | Radical cystectomy |
| RCT | Randomized controlled trial |
| RFS | Recurrence-free survival |
| RVU | Relative value unit |
| SAE | Serious adverse event |
| SD | Standard deviation |
| SEER | Surveillance, Epidemiology, and End Results |
| SUO | Society of Urologic Oncology |
| TRAE | Treatment-related adverse event |
| TURBT | Transurethral resection of bladder tumor |
| UC | Urothelial carcinoma |
| USD | U.S. dollars |
| utDNA | Urinary tumor DNA |
| VP | Viral particles |
| WAC | Wholesale acquisition cost |
| WHO | World Health Organization |
| wRR | Weighted risk ratio |
| WTP | Willingness to pay |